Sparsentan

(Filspari®)

Sparsentan

Drug updated on 11/17/2023

Dosage FormTablet (oral: 200 mg, 400 mg)
Drug ClassEndothelin and angiotensin II receptor antagonist
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.

Product Monograph / Prescribing Information

Document TitleYearSource
Filspari (sparsentan) Prescribing Information. 2023Travere Therapeutics, Inc., San Diego, CA

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Data not availableSubjects
F: undefined%
M: undefined%
2023The Lancet